Is Rapport Therapeutics, Inc. Common Stock (RAPP) a good stock to buy?

Olyth's institutional analysis of RAPP reveals an Altman Z-Score of 26.38 and a Piotroski F-Score of 1/9. These metrics, combined with its 5-year revenue trend ($0.00B most recent), help investors decide if RAPP fits their risk profile.

What is the current P/E ratio for RAPP?

As of the latest trading session, Rapport Therapeutics, Inc. Common Stock (RAPP) has a trailing P/E ratio of -13.64.

Who is the CEO of Rapport Therapeutics, Inc. Common Stock?

The current Chief Executive Officer of Rapport Therapeutics, Inc. Common Stock is Abraham N. Ceesay.

What was RAPP's revenue for the last 5 years?

According to its latest income statements, Rapport Therapeutics, Inc. Common Stock reported annual revenues of $0.00B (2025), $0.00B (2024), $0.00B (2023), $0.00B (2022) respectively.

Does RAPP pay a dividend?

Rapport Therapeutics, Inc. Common Stock does not currently pay a dividend to its shareholders.

How much debt and cash flow does RAPP have?

In its latest reporting period, Rapport Therapeutics, Inc. Common Stock generated $-0.09B in Free Cash Flow against a total debt load of $0.01B.

What is the Price-to-Book (P/B) ratio of Rapport Therapeutics, Inc. Common Stock?

The Price-to-Book (P/B) ratio for Rapport Therapeutics, Inc. Common Stock (RAPP) is currently 3.14.

What is the Price-to-Sales (P/S) ratio of RAPP?

Based on trailing twelve-month data, Rapport Therapeutics, Inc. Common Stock (RAPP) trades at a Price-to-Sales (P/S) ratio of 0.00.

What is Rapport Therapeutics, Inc. Common Stock's Return on Equity (ROE)?

Rapport Therapeutics, Inc. Common Stock (RAPP) has a Return on Equity (ROE) of -28.85%, representing its profitability relative to shareholder equity.

RAPP

Rapport Therapeutics, Inc. Common Stock · Healthcare

32.38

3.57%(-1.20)

Prev. Close

38.70

19.52%(+6.32)

Pre-market

Last Updated: — ET

52W L: $7.7352W H: $42.27

$33.20

CHG+1.00 (+3.11%)

H$34.26

L$26.07

VOL5M

RAPP (1h)

Company Profile

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2024-06-07

Beta

1.10

Websitewww.rapportrx.com↗

RAPP

Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Target Price at $51.40

Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting

CRCAM Toulouse 31 - Rapport financier annuel 2025

All You Need to Know About Rapport Therapeutics, Inc. (RAPP) Rating Upgrade to Buy

Rapport Therapeutics, Inc. (RAPP) Presents at Stifel 2026 Virtual CNS Forum Transcript